Single dose pharmacokinetics and bioavailability of butyryl glucosamine in the rat

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 9, Issue 3, 2006, Pages 359-364

  Aghazadeh Habashi, Ali ^a   Ibrahim, Alyaa ^a   Carran, John ^b   Anastassiades, Tassos ^b   Jamali, Fakhreddin ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSAMINE DERIVATIVE; N BUTYRYLGLUCOSAMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; JUGULAR VEIN; MALE; NONHUMAN; RAT; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; DRUG ADMINISTRATION SCHEDULE; FOOD-DRUG INTERACTIONS; GASTROINTESTINAL TRACT; GLUCOSAMINE; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33947514497     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Hopman WM, Towheed TE, Gao Y, Berger C, Joseph L, Vik SA, Hanley DA, Carran J, Anastassiades T. Prevalence of and factors associated with glucosamine use in Canada. Osteoarthritis Cartilage. 2006 Jul 8 (EPub ahead of print).
2. TE Towheed, L Maxwell, TP Anastassiades, B Shea, J Houpt, V Robinson, MC Hochberg and G Wells. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev.CD002946 Apr 18 2005
3. TS Barclay, C Tsourounis and G M McCart. Glucosamine. The Annals of Pharmacotherapy. 32: 574-579, 1998.
4. M W Poustie, J Carran, K McEleney, S J Dixon, T P Anastassiades, and S M. Bernier. N-butyryl Glucosamine Increases Matrix Gen Expression by Chondrocytes. J. of Pharm. Exp. Therapeutics. 311:610-616, 2004.
5. T P Anastassiades, JR Carran, X-J Yang et al. ANABU™: A Promising New Class of Carbohydrate-based Drugs for the Treatment of Bone and Joint Disorders. American College of Rheumatology, 70th annual meeting, Nov10-15, 2006.
6. X Susanne. AC Wang, Annie, M Dumitriu, MD Grynpas, J Carran, D Wainman and T Anastassiades. Disease-modifying effects of N-butyryl glucosamine in a streptococcal cell wall (SCW) induced arthritis model in rats. J. Reumatol. In press.
7. A Aghazadeh-Habashi, J. Carran T Anastassiades and F Jamali, High performance liquid chromatographic determination of N-butyryl glucosamine in rat plasma. J. of Chromatoger. 819:91-6, 2005.
8. Chiou WL, Ma C, Chung SM, Wu TC, Jeong HY. Similarity in the linear and non-linear oral absorption of drugs between human and rat. Int J Clin Pharmacol Ther 2000 Nov;38:532-9
9. A Aghazadeh-Habashi, S Sattari, F Pasutto and F Jamali. High performance liquid chromatographic determination of glucosamine in rat plasma. J. Pharm. Pharm. Sci. 5:176-80, 2002.
10. M. Gibaldi, Pharmacokinetics. 2nd edition, New York: Marcel Dekker, Inc., 33-39, 149-153, 409-417, 1982.
11. A Aghazadeh-Habashi, S Sattari, F Pasutto and F Jamali. Single dose pharmacokinetics and bioavailability of glucosamine in the rat. J. Pharm. Pharm. Sci. 5:181-4, 2002.
12. M Uldry, M Ibberson, M Hosokawa, B Thorenes. GLUT2 is a high affinity glucosamine transporter. FEBS Letters. 524:199-203, 2002.
13. D Fleisher, C Li, Y Zhou, LH Pao, A Karim. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications. Clin Pharmacokinet. 36:233-54, 1999.